ClinicalTrials.gg
Status unknownNCT01788904FARAMISUpdated Dec 12, 2013

Plasma i-FABP as Predictor for Irreversible Bowel Ischemia

An observational study in Acute Mesenteric Ischemia and Bowel Necrosis, sponsored by University Hospital Regensburg. Status unknown at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-12.

Sponsored by University Hospital Regensburg · Observational

The sponsor has not verified this record recently (last verified Dec 2013), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
24
Ages
18 Years and older
Sex
All
01

Study summary

In the FARAMIS study, we aim to investigate the longitudinal course of intestinal plasma fatty acid binding protein (i-FABP) in patients with acute mesenteric ischemia (AMI) undergoing primary percutaneous angiographic intervention.

The investigators postulate that patients with fully re-established intestinal blood flow and vital intestines will display a significant drop of plasmatic i-FABP within 24 hours, while patients requiring subsequent intestinal resection due to irreversible bowel necrosis will not.

If true, patients requiring laparotomy and bowel resection could be identified and patients in whom angiographic intervention led to successful cure of disease would not be exposed to potentially perilous surgery.

Read the detailed description

Intestinal plasma fatty acid binding proteins (i-FABP) have been introduced as a powerful marker for the diagnosis of intestinal ischemia. Based on several small studies, this marker is referred to as a sensitive indicator for intestinal ischemia. I-FABP is characterized by its short half-time of eleven minutes in blood circulation, which might allow "real-time" monitoring of necrotic intestinal segments.

Subjects meeting the in-/exclusion criteria will undergo five to six blood collections: one baseline assessment before revascularization, three assessments directly after angiographic intervention (5/30/120 minutes), and one assessment after 24 hours. An additional blood collection will be performed in patients who underwent subsequent surgery. In addition, clinical exams of the patient are carried out.

Subjects will be observed for 72 hours after percutaneous revascularization and retrospectively classified depending on the clinical course: recovering patients or patients undergoing surgery without signs of necrotic segments will be attributed to group A. Patients in whom intestinal necrosis is confirmed by surgery or autopsy will belong to group B. For all patients, clinical and laboratory findings will be reported in a descriptive manner.

To evaluate whether the post-interventional course of plasmatic i-FABP is a reliable predictor for successful revascularization, the minimum level of i-FABP at the time points 5, 30 and 120 Minutes is divided by the baseline (= before intervention) level of i-FABP. This ratio (R) reflects the decrease (or increase) of i-FABP after revascularization. Receiver operating characteristic (ROC)-analysis will be carried out and the area under the curve will be determined for different R-values (e.g. 0.3, 0.5, 0.7).

We postulate that patients with fully re-established intestinal blood flow and vital intestines will display a significant drop of plasmatic i-FAPB within 24 hours, while patients requiring subsequent intestinal resection due to irreversible bowel necrosis will not.

02

Conditions studied

  • Acute Mesenteric Ischemia
  • Bowel Necrosis

Keywords

  • Acute mesenteric ischemia
  • Percutaneous endovascular revascularization
  • Intestinal plasma fatty acid binding protein (i-FABP)
  • Bowel necrosis
03

In context

Mesenteric Ischemia

40 studies on the registry are indexed under Mesenteric Ischemia; 14 are open to participants now.

This study's planned enrollment of 24 is below the median of 154 across 26 observational studies indexed under Mesenteric Ischemia.

Browse Mesenteric Ischemia studies →

Lead sponsor

University Hospital Regensburg is the lead sponsor of 20 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Tertiary care clinic

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of acute mesenteric ischemia due to stenosis of the superior mesenteric artery, thromboembolization of the superior mesenteric artery, non-occlusive mesenteric ischemia or acute portal vein thrombosis (as confirmed by CT scan)
  • The vascular anatomy is suitable for percutaneous revascularization
  • A primary endovascular re-vascularisation approach is intended based on an interdisciplinary decision by the visceral surgeon, the vascular surgeon and interventional radiologist. This therapeutic decision is made independently of the proposed FARAMIS study.
  • A peripheral or central line is present to perform repeated blood collections

Exclusion criteria

Exclusion Criteria:

  • Clinically or imaging results indicating that perforation of the bowel is present or suspected
  • Hemodynamic instability (shock)
  • Pre-existing severe liver or kidney damage (defined as spontaneous >2 or creatinine >2 mg/dl.)
  • Anemia with concentration \< 7g/dl
  • Pediatric patients
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
24 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with acute mesenteric ischemia

    Patients with acute mesenteric ischemia meeting the in-/exclusion criteria

06

What researchers measure

Primary outcomes

  1. Post-interventional course of plasmatic i-FABP as reliable predictor for successful bowel revascularization

    Subjects will be observed for 72 hours after percutaneous revascularization. Patients will then be divided into two groups: patients not requiring surgery and not dying from intestinal necrosis will be allocated to group A. Subjects who undergo surgery without signs of necrotic segments will also be attributed to group A. Patients in whom intestinal necrosis is confirmed by surgery or autopsy will belong to group B. To evaluate whether the post-interventional course of plasmatic i-FABP is a reliable predictor for successful revascularization, the minimum level of i-FABP at the time points 5, 30 and 120 Minutes is divided by the baseline (= before intervention) level of i-FABP. This ratio (R) reflects the decrease (or increase) of i-FABP after revascularization. ROC-analysis will be carried out and the area under the curve will be determined for different R-values.

    Time frame: 72 hours

Secondary outcomes

  1. Baseline level of i-FABP as predictor of bowel necrosis

    Time frame: 72 hours

Other outcomes

  1. Levels of i-FABP, interleukine 6 and 8

    Association of increased levels of i-FABP, interleukine 6 and 8 with extension of intestinal necrosis according to the pathology report and occurrence of organ failure

    Time frame: 72 hours

07

Study locations

1 of 1 sites recruiting
  • University Hospital Regensburg
    Regensburg, 93053, Germany
    Recruiting
    • Philipp Renner, MD · Contactphilipp.renner@ukr.de · +49 151 1944 5787
    • Peter Heiss, MD · Contactpeter.heiss@ukr.de · +49 941 944 7401
    • Peter Heiss, MD, MS · Principal investigator
    • Philipp Renner, MD · Sub investigator
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01788904
Lead sponsor
University Hospital Regensburg
Collaborators
William Cook Europe
Responsible party
Peter Heiss (Peter Heiss, MD, MS, University Hospital Regensburg) — Principal investigator
First posted
Feb 11, 2013
Start date
Feb 2013
Primary completion
Jun 2017 (estimated)
Completion
Jun 2017 (estimated)
Last update
Dec 12, 2013

Study contacts

Peter G Heiss, MD, MS
Contact
peter.heiss@ukr.de
+49 941 944 7401
Philipp Renner, MD
Contact
philipp.renner@ukr.de
+49 151 1944 5787
Peter Heiss, MD, MS
principal investigator · University Hospital Regensburg Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion